Literature DB >> 27226003

Recurrent coma and fever in familial hemiplegic migraine type 2. A prospective 15-year follow-up of a large family with a novel ATP1A2 mutation.

N Pelzer1, D E Blom1, A H Stam1, L S Vijfhuizen2, Atm Hageman3, J A van Vliet4, M D Ferrari1, Amjm van den Maagdenberg1,2, J Haan1,5, G M Terwindt1.   

Abstract

Background Familial hemiplegic migraine (FHM) is a rare monogenic migraine subtype characterised by attacks associated with transient motor weakness. Clinical information is mainly based on reports of small families with only short follow-up. Here, we document a prospective 15-year follow-up of an extended family with FHM type 2. Patients and methods After diagnosing FHM in a patient with severe attacks associated with coma and fever, we identified eight more family members with FHM and one with possible FHM. All family members were prospectively followed for 15 years. In total 13 clinically affected and 21 clinically non-affected family members were genetically tested and repeatedly investigated. Results A novel p.Arg348Pro ATP1A2 mutation was found in 14 family members: 12 with clinical FHM, one with psychomotor retardation and possible FHM, and one without FHM features. In 9/12 (75%) family members with genetically confirmed FHM, attacks were severe, long-lasting, and often associated with impaired consciousness and fever. Such attacks were frequently misdiagnosed and treated as viral meningitis or stroke. Epilepsy was reported in three family members with FHM and in the one with psychomotor retardation and possible FHM. Ataxia was not observed. Conclusion FHM should be considered in patients with recurrent coma and fever.

Entities:  

Keywords:  Familial hemiplegic migraine; HaNDL; brainstem aura; coma; confusional migraine; epilepsy

Mesh:

Substances:

Year:  2016        PMID: 27226003     DOI: 10.1177/0333102416651284

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  8 in total

1.  Cognitive dysfunction in a patient with migraine and APT1A2 mutation: a case report.

Authors:  Pian Wang; Yan-Rong Yang; Hong-Bo Zhang; Jiang-Hong Wang; Yan Wang
Journal:  Neurol Sci       Date:  2021-04-27       Impact factor: 3.307

2.  Familial Hemiplegic Migraine with Severe Attacks: A New Report with ATP1A2 Mutation.

Authors:  E Martínez; R Moreno; L López-Mesonero; I Vidriales; M Ruiz; A L Guerrero; J J Tellería
Journal:  Case Rep Neurol Med       Date:  2016-10-13

Review 3.  Exploring the role of microglia in cortical spreading depression in neurological disease.

Authors:  Mamoru Shibata; Norihiro Suzuki
Journal:  J Cereb Blood Flow Metab       Date:  2017-01-01       Impact factor: 6.200

Review 4.  The Structure and Function of the Na,K-ATPase Isoforms in Health and Disease.

Authors:  Michael V Clausen; Florian Hilbers; Hanne Poulsen
Journal:  Front Physiol       Date:  2017-06-06       Impact factor: 4.566

5.  A novel ATP1A2 mutation in a patient with hypokalaemic periodic paralysis and CNS symptoms.

Authors:  Marisol Sampedro Castañeda; Edmar Zanoteli; Renata S Scalco; Vinicius Scaramuzzi; Vitor Marques Caldas; Umbertina Conti Reed; Andre Macedo Serafim da Silva; Benjamin O'Callaghan; Rahul Phadke; Enrico Bugiardini; Richa Sud; Samuel McCall; Michael G Hanna; Hanne Poulsen; Roope Männikkö; Emma Matthews
Journal:  Brain       Date:  2018-12-01       Impact factor: 13.501

Review 6.  Roles of Key Ion Channels and Transport Proteins in Age-Related Hearing Loss.

Authors:  Parveen Bazard; Robert D Frisina; Alejandro A Acosta; Sneha Dasgupta; Mark A Bauer; Xiaoxia Zhu; Bo Ding
Journal:  Int J Mol Sci       Date:  2021-06-07       Impact factor: 5.923

7.  A case report of atypical hemiplegic migraine with nonheadache onset in a Chinese child.

Authors:  Hui Chen; Xiaolan Sun; Ruiyan Wang; Zhaoshi Yi; Zhixin Huang; Jihua Xie; Xiongying Yu; Yong Chen; Jianmin Zhong
Journal:  BMC Neurol       Date:  2021-07-06       Impact factor: 2.474

8.  Exploring Neuronal Vulnerability to Head Trauma Using a Whole Exome Approach.

Authors:  Omar Ibrahim; Heidi G Sutherland; Neven Maksemous; Robert Smith; Larisa M Haupt; Lyn R Griffiths
Journal:  J Neurotrauma       Date:  2020-05-04       Impact factor: 5.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.